Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma
Sarit Assouline(Jewish General Hospital), Peter Martin(Northwestern University), A-M Hui(Takeda (United States)), Solomon I. Hamburg(Tower Cancer Research Foundation), Elizabeth Chang(University of the Sunshine Coast), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Ruben Reyes(The University of Texas MD Anderson Cancer Center), Bruce D. Cheson(Center for Cancer and Blood Disorders), Jie Yu(KU Leuven), Neeraj Gupta(Takeda (United States)), Yaping Shou(Takeda (United States)), Alessandra Di Bacco(Millennium Engineering and Integration (United States))
Cited by 48
Related Papers
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
|Journal of Clinical Oncology|2003|2.7k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k